Vittorio C - Search Results

1

The risk of malignancy associated with psoriasis.

Margolis D, Bilker W, Hennessy S, Vittorio C, Santanna J, Strom BL. Margolis D, et al. Among authors: vittorio c. Arch Dermatol. 2001 Jun;137(6):778-83. Arch Dermatol. 2001. PMID: 11405770

2

Rate of body dysmorphic disorder in dermatology patients.

Phillips KA, Dufresne RG Jr, Wilkel CS, Vittorio CC. Phillips KA, et al. Among authors: vittorio cc. J Am Acad Dermatol. 2000 Mar;42(3):436-41. doi: 10.1016/s0190-9622(00)90215-9. J Am Acad Dermatol. 2000. PMID: 10688713

3

Preventive techniques to limit glucocorticoid-induced side effects.

Vittorio CC, Werth VP. Vittorio CC, et al. Adv Dermatol. 2000;16:273-97; discussion 298. Adv Dermatol. 2000. PMID: 11094631 Review. No abstract available.

4

Papulosquamous disorders of the elderly.

van Voorhees A, Vittorio CC, Werth VP. van Voorhees A, et al. Among authors: vittorio cc. Clin Geriatr Med. 2001 Nov;17(4):739-68, vii. doi: 10.1016/s0749-0690(05)70096-3. Clin Geriatr Med. 2001. PMID: 11535426 Review.

5

Regression of multifocal, skin-restricted, CD30-positive large T-cell lymphoma with interferon alfa and bexarotene therapy.

French LE, Shapiro M, Junkins-Hopkins JM, Vittorio CC, Rook AH. French LE, et al. Among authors: vittorio cc. J Am Acad Dermatol. 2001 Dec;45(6):914-8. doi: 10.1067/mjd.2001.117519. J Am Acad Dermatol. 2001. PMID: 11712039

6

Denileukin diftitox for the treatment of panniculitic lymphoma.

McGinnis KS, Shapiro M, Junkins-Hopkins JM, Smith M, Lessin SR, Vittorio CC, Rook AH. McGinnis KS, et al. Among authors: vittorio cc. Arch Dermatol. 2002 Jun;138(6):740-2. doi: 10.1001/archderm.138.6.740. Arch Dermatol. 2002. PMID: 12056952 No abstract available.

7

New biologic agents for the treatment of cutaneous T-cell lymphoma.

Vittorio CC, Junkins-Hopkins JM, McGinnis KS, Shapiro M, Wysocka M, Zaki MH, French LE, Rook AH. Vittorio CC, et al. Recent Results Cancer Res. 2002;160:321-8. doi: 10.1007/978-3-642-59410-6_37. Recent Results Cancer Res. 2002. PMID: 12079230 Review.

8

Treatment of cutaneous T-cell lymphoma with combined immunomodulatory therapy: a 14-year experience at a single institution.

Suchin KR, Cucchiara AJ, Gottleib SL, Wolfe JT, DeNardo BJ, Macey WH, Bromley PG, Vittorio CC, Rook AH. Suchin KR, et al. Among authors: vittorio cc. Arch Dermatol. 2002 Aug;138(8):1054-60. doi: 10.1001/archderm.138.8.1054. Arch Dermatol. 2002. PMID: 12164743

9

Assessment of tumor burden and treatment response by 18F-fluorodeoxyglucose injection and positron emission tomography in patients with cutaneous T- and B-cell lymphomas.

Shapiro M, Yun M, Junkins-Hopkins JM, Vittorio CC, Schulman N, Saidman BH, Fried RG, Rook AH, Alavi A. Shapiro M, et al. Among authors: vittorio cc. J Am Acad Dermatol. 2002 Oct;47(4):623-8. doi: 10.1067/mjd.2002.124076. J Am Acad Dermatol. 2002. PMID: 12271315

10

Novel multimodality biologic response modifier therapy, including bexarotene and long-wave ultraviolet A for a patient with refractory stage IVa cutaneous T-cell lymphoma.

Shapiro M, Rook AH, Lehrer MS, Junkins-Hopkins JM, French LE, Vittorio CC. Shapiro M, et al. Among authors: vittorio cc. J Am Acad Dermatol. 2002 Dec;47(6):956-61. doi: 10.1067/mjd.2002.124816. J Am Acad Dermatol. 2002. PMID: 12451388 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results